Seeking Alpha

Trius Therapeutics (TSRX +1.2%) comments on Congress's approval of the Prescription Drug Users...

Trius Therapeutics (TSRX +1.2%) comments on Congress's approval of the Prescription Drug Users Fee Act, saying it contains key incentives for antibiotic drug developers. The Act, which is expected to be signed into law by President Obama next week, will provide drug developers with new regulatory options to aid in the development of new treatments for infections caused by drug resistant bacteria.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs